Alisson Olbera

Alisson Olbera

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
VPVinicius Skau Perino
Vinicius Skau Perino
Lucas Vinícius de Oliveira FerreiraLucas Vinícius de Oliveira Ferreira
Lucas Vinícius de Oliveira Ferreira
BKBeatriz da Costa Kamura
Beatriz da Costa Kamura
NCNatielly Dias Chimenes
Natielly Dias Chimenes
AOAlisson Olbera
Alisson Olbera
Rogério Martins AmorimRogério Martins Amorim
Rogério Martins Amorim
The endocannabinoid system regulates key biological functions such as neuroprotection, pain modulation, inflammation, and immunomodulation. Cannabis-based therapies have gained attention due to the therapeutic potential of their bioactive compounds, particularly phytocannabinoids like cannabidiol (CBD), which exhibit anti-inflammatory, neuroprotective, and immunomodulatory properties. Mesenchymal stem cells (MSCs) are widely studied for their regenerative and immunomodulatory potential. This study evaluated the effects of priming canine adipose tissue-derived MSCs (cAT-MSCs) with a CBD-rich cannabis extract on cell morphology, viability, neurotrophic factor gene expression, and cytokine gene and protein expression. cAT-MSCs (n = 5) were primed for 24 h and divided into three groups: Control (C, unprimed), D1 (2.25 µM CBD), and D2 (225 nM CBD). No morphological or viability changes were observed. Gene expression analysis showed that groups D1 and D2 exhibited increased HGF expression. D1 also showed increased IDO and decreased BDNF expression. In contrast, no significant changes were observed in GDNF, IL-10, TNF-α, IFN-γ, or PTGES2. Regarding the cytokine profile, GM-CSF, IL-2, and IL-10 were undetectable. Notably, IL-8 and MCP-1 levels were significantly reduced in D1 compared to the control. These findings suggest that CBD priming modulates key regenerative and inflammatory mediators in cAT-MSCs, supporting its potential application in enhancing the efficacy of cell-based therapies.

1 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VPVinicius Skau Perino
Vinicius Skau Perino
Lucas Vinícius de Oliveira FerreiraLucas Vinícius de Oliveira Ferreira
Lucas Vinícius de Oliveira Ferreira
BKBeatriz da Costa Kamura
Beatriz da Costa Kamura
NCNatielly Dias Chimenes
Natielly Dias Chimenes
AOAlisson Olbera
Alisson Olbera
Rogério Martins AmorimRogério Martins Amorim
Rogério Martins Amorim
The endocannabinoid system regulates key biological functions such as neuroprotection, pain modulation, inflammation, and immunomodulation. Cannabis-based therapies have gained attention due to the therapeutic potential of their bioactive compounds, particular-ly phytocannabinoids like cannabidiol (CBD), which exhibit anti-inflammatory, neuro-protective, and immunomodulatory properties. Mesenchymal stem cells (MSCs) are widely studied for their regenerative and immunomodulatory potential. This study evaluated the effects of priming canine adipose tissue-derived MSCs (cAT-MSCs) with a CBD-rich can-nabis extract on cell morphology, viability, neurotrophic factor gene expression, and cyto-kine gene and protein expression. cAT-MSCs (n = 5) were primed for 24 hours and divided into three groups: Control (C, unprimed), D1 (2.25 µM CBD), and D2 (225 nM CBD). No morphological or viability changes were observed. Gene expression analysis showed that groups D1 and D2 exhibited increased HGF expression. D1 also showed increased IDO and decreased BDNF expression. In contrast, no significant changes were observed in GDNF, IL-10, TNF-α, IFN-γ, or PTGES2. Regarding the cytokine profile, GM-CSF, IL-2, and IL-10 were undetectable. Notably, IL-8 and MCP-1 levels were significantly reduced in D1 compared to control. These findings suggest that CBD priming modulates key regenerative and inflammatory mediators in cAT-MSCs, supporting its potential application in en-hancing the efficacy of cell-based therapies.